RxDoctor Payments Data

Jean Ying-Chang, MD

Child & Adolescent Psychiatry · Denville, NJNPI 1386670800

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 26 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 7 manufacturers reported payments, led by Teva Pharmaceuticals USA, Inc. at 34.3% of the total. 2025 is the largest year on record at $177, 2.1 times the $86 reported in 2021.

$408in general payments, 2019–2025

Across 26 payments — averaging $15.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$140
  • Otsuka America Pharmaceutical, Inc.$100
  • Johnson & Johnson$90
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$35
  • AbbVie$16
  • Alkermes, Inc.$14
  • plus $13 from 1 others

What the payments were for

  • Food & beverage$408100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$408 in reported general payments places this provider in the 65th percentile of 137 child & adolescent psychiatry providers in New Jersey.

See all child & adolescent psychiatry providers in New Jersey

Medicare billing

Part B allowed, 2024
$18,639
Medicare patients
29
Services billed
168

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl13$21,612
Aripiprazole56$8,370
Paliperidone ErPaliperidone39$3,317
Quetiapine Fumarate74$2,120
Divalproex Sodium ErDivalproex Sodium27$1,896
Fluvoxamine Maleate25$1,656
Clozapine13$1,521
Hydroxyzine Hcl67$1,420
Desvenlafaxine Succinate ErDesvenlafaxine Succinate44$1,321
Haloperidol36$1,132
Lamotrigine90$1,130
Olanzapine42$1,101
Oxcarbazepine36$851
Buspirone Hcl61$752
Clonazepam74$595

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$16$21,61213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 137 child & adolescent psychiatry providers in New Jersey.

Other child & adolescent psychiatry in Denville

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →